Mortality after transcatheter versus surgical aortic valve replacement: an updated meta-analysis of randomised trials
Authors:
- ALICE (All-Literature Investigation of Cardiovascular Evidence) GroupAGALICE (All-Literature Investigation of Cardiovascular Evidence) Group
- H. TakagiHTH. Takagi
Open Access
- 1 June 2020
- journal article
- research article
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 28 (6) , 320-333
Abstract
Background: To determine whether transcatheter aortic valve implantation (TAVI) improves early (30-day) and midterm (1-year) mortality compared with surgical aortic valve replacement (SAVR), we performed an updated meta-analysis of all the currently available randomised controlled trials (RCTs).Methods: To identify all RCTs providing both 30-day and 1‑year mortality after TAVI versus SAVR, PubMed and ClinicalTrials.gov were searched up to and including July 2019. A risk difference (RD) and its 95% confidence interval were generated using data of prespecified outcomes in both the TAVI and SAVR groups. Study-specific estimates were pooled using inverse variance-weighted averages of RDs in the random-effects model.Results: We identified seven eligible high-quality RCTs including a total of 7631 as-treated patients. Pooled analyses demonstrated significantly lower 30-day (RD −0.60%;p = 0.046) and 1‑year all-cause mortality (RD −1.12%;p = 0.03) after TAVI than after SAVR. No funnel plot asymmetry was detected for 30-day and 1‑year mortality. Meta-regression analyses indicated that RDs of 30-day and 1‑year mortality between TAVI and SAVR were not modulated by mean Society of Thoracic Surgeons Predicted Risk of Mortality score. Bleeding complications at 30 days and 1 year and stage 2/3 acute kidney injury at 30 days were significantly less frequent after TAVI than after SAVR, whereas major vascular complications and new permanent pacemaker implantation at 30 days and 1 year were significantly more frequent after TAVI than after SAVR.Conclusion: The best evidence from the present meta-analysis of all the currently available RCTs suggests that TAVI may reduce 30-day and 1‑year all-cause mortality compared with SAVR.Keywords
This publication has 40 references indexed in Scilit:
- Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk PatientsNew England Journal of Medicine, 2016
- Efficacy and safety of transcatheter aortic valve replacement in intermediate surgical risk patients: A systematic review and meta‐analysisCatheterization and Cardiovascular Interventions, 2016
- New-Onset Left Bundle Branch Block Induced by Transcutaneous Aortic Valve ImplantationThe American Journal of Cardiology, 2016
- Mortality in patients requiring pacemaker implantation following transcatheter aortic valve replacement: Insights from a systematic review and meta-analysisInternational Journal of Cardiology, 2014
- Comparison of Pulmonary Complications in Patients Undergoing Transcatheter Aortic Valve Implantation Versus Open Aortic Valve ReplacementJournal of Cardiothoracic and Vascular Anesthesia, 2014
- Beyond intention to treat: What is the right question?Clinical Trials, 2013
- Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve ReplacementJACC, 2013
- Patients With Severe Aortic Stenosis and Reduced Ejection Fraction: Earlier Recovery of Left Ventricular Systolic Function After Transcatheter Aortic Valve Implantation Compared With Surgical Valve ReplacementEchocardiography, 2013
- A prospective, randomised trial of transapical transcatheter aortic valve implantation vs. surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trialEuroIntervention, 2012
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsNew England Journal of Medicine, 2011